Published in Am J Pathol on May 04, 2011
Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers. J Exp Clin Cancer Res (2016) 1.40
Friend or foe: role of E-cadherin in prostate cancer metastasis. Transl Androl Urol (2016) 1.39
Dishonorable discharge: the oncogenic roles of cleaved E-cadherin fragments. Cancer Res (2012) 1.22
The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget (2013) 1.13
SNAI1 is critical for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer (2014) 0.95
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS One (2012) 0.92
Transcriptome-wide landscape of pre-mRNA alternative splicing associated with metastatic colonization. Mol Cancer Res (2014) 0.91
Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep (2013) 0.91
Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer. PLoS One (2014) 0.90
Id2 complexes with the SNAG domain of Snai1 inhibiting Snai1-mediated repression of integrin β4. Mol Cell Biol (2013) 0.89
High expression of ZEB1 correlates with liver metastasis and poor prognosis in colorectal cancer. Oncol Lett (2012) 0.89
Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol (2013) 0.88
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol (2014) 0.87
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci (2014) 0.87
The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets. Oncotarget (2015) 0.87
Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. Transl Oncol (2014) 0.87
Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling. Hepatology (2016) 0.85
SRC: marker or actor in prostate cancer aggressiveness. Front Oncol (2014) 0.83
Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer. Mol Cancer Res (2014) 0.80
Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling. Chin J Cancer (2017) 0.78
High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett (2015) 0.78
Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci (2016) 0.78
PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med (2015) 0.78
Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget (2015) 0.78
Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med (2013) 0.78
Cellular Plasticity in Prostate Cancer Bone Metastasis. Prostate Cancer (2015) 0.78
Aberrant expression of Notch1/numb/snail signaling, an epithelial mesenchymal transition related pathway, in adenomyosis. Reprod Biol Endocrinol (2015) 0.77
CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Res (2016) 0.77
The glycosyltransferase LARGE2 is repressed by Snail and ZEB1 in prostate cancer. Cancer Biol Ther (2015) 0.77
Distinct routes to metastasis: plasticity-dependent and plasticity-independent pathways. Oncogene (2016) 0.77
Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. Cytokine (2016) 0.76
Novel therapeutic strategy targeting the Hedgehog signalling and mTOR pathways in biliary tract cancer. Br J Cancer (2015) 0.76
Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases. Clin Exp Metastasis (2015) 0.76
The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. Mol Oncol (2017) 0.76
Friend turned foe: E-cadherin perversely protects micrometastases. Transl Androl Urol (2017) 0.75
Association of molecular biomarkers expression with biochemical recurrence in prostate cancer through tissue microarray immunostaining. Oncol Lett (2015) 0.75
A Pathway to Personalizing Therapy for Metastases Using Liver-on-a-Chip Platforms. Stem Cell Rev (2017) 0.75
Microenvironmental interactions and expression of molecular markers associated with epithelial-to-mesenchymal transition in colorectal carcinoma. Int J Clin Exp Pathol (2015) 0.75
Biomimetic Hydrogels Incorporating Polymeric Cell-Adhesive Peptide To Promote the 3D Assembly of Tumoroids. Biomacromolecules (2016) 0.75
EMT: Present and future in clinical oncology. Mol Oncol (2017) 0.75
Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin. Breast Cancer Res (2017) 0.75
Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. Stem Cells Int (2017) 0.75
Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer (2007) 18.69
Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol (2005) 11.46
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Genes that mediate breast cancer metastasis to the brain. Nature (2009) 8.23
Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest (2009) 6.70
Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev (2006) 5.45
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Adherens junctions: from molecules to morphogenesis. Nat Rev Mol Cell Biol (2010) 3.97
The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med (Berl) (2004) 3.32
ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell (2010) 3.25
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res (2006) 3.12
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol (2009) 2.89
Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res (2008) 2.67
Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One (2010) 2.63
A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res (2007) 2.57
Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res (1992) 2.55
Src signaling in cancer invasion. J Cell Physiol (2010) 2.44
Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res (2010) 2.43
A role for cadherins in tissue formation. Development (1996) 2.32
Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer (2010) 2.31
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci U S A (2010) 2.16
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer (2007) 1.75
Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia (2004) 1.71
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol (2001) 1.68
Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer. Semin Cell Dev Biol (2004) 1.55
Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum Pathol (2005) 1.54
ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell (2009) 1.52
Transcriptional profiling of mouse and human ES cells identifies SLAIN1, a novel stem cell gene. Dev Biol (2006) 1.47
Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer. Histopathology (2007) 1.45
Expression of Zfhep/deltaEF1 protein in palate, neural progenitors, and differentiated neurons. Gene Expr Patterns (2003) 1.43
Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A (2005) 1.40
s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev (2010) 1.39
E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology (1999) 1.37
Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol (1996) 1.31
Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone (2010) 1.27
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. PLoS One (2007) 1.26
Microenvironmental regulation of E-cadherin-mediated adherens junctions. Front Biosci (2008) 1.25
Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann N Y Acad Sci (2004) 1.24
ZEB proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle (2010) 1.23
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate (2008) 1.19
The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev (2009) 1.18
Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer (1997) 1.17
Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol (2001) 1.17
The pluripotency of hair follicle stem cells. Cell Cycle (2006) 1.13
A transcriptional roadmap to the induction of pluripotency in somatic cells. Stem Cell Rev (2010) 1.09
Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum Pathol (2001) 1.04
Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer (1996) 1.02
Cell-specific phosphorylation of Zfhep transcription factor. Biochem Biophys Res Commun (2002) 1.02
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome. J Biol Chem (1999) 1.01
Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem (2004) 1.00
E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol (2010) 0.99
The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate (2007) 0.98
Meta-analysis of differentiating mouse embryonic stem cell gene expression kinetics reveals early change of a small gene set. PLoS Comput Biol (2006) 0.98
Expression of E-cadherin in primary prostate cancer: correlation with clinical features. Br J Urol (1998) 0.86
An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol (2006) 0.83
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The accessible chromatin landscape of the human genome. Nature (2012) 16.86
A map of the interactome network of the metazoan C. elegans. Science (2004) 15.60
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A (2011) 10.56
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods (2010) 6.25
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
MicroRNA profiling: approaches and considerations. Nat Rev Genet (2012) 4.39
Functional genomic analysis of RNA interference in C. elegans. Science (2005) 4.36
Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods (2009) 4.34
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Multiple integrated copies and high-level production of the human retrovirus XMRV (xenotropic murine leukemia virus-related virus) from 22Rv1 prostate carcinoma cells. J Virol (2009) 3.16
MicroRNA discovery and profiling in human embryonic stem cells by deep sequencing of small RNA libraries. Stem Cells (2008) 3.14
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
Zeb1 links epithelial-mesenchymal transition and cellular senescence. Development (2008) 2.55
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Empirically controlled mapping of the Caenorhabditis elegans protein-protein interactome network. Nat Methods (2009) 2.50
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37
Post-transcriptional generation of miRNA variants by multiple nucleotidyl transferases contributes to miRNA transcriptome complexity. Genome Res (2011) 2.34
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
The limits of reductionism in medicine: could systems biology offer an alternative? PLoS Med (2006) 2.13
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci (2012) 2.12
Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. Cell Stem Cell (2009) 2.09
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Supervised normalization of microarrays. Bioinformatics (2010) 2.00
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology (2003) 1.94
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer (2006) 1.88
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol (2009) 1.84
Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate (2002) 1.78
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab (2008) 1.78
TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol (2009) 1.75
Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer (2005) 1.73
Digital genomic quantification of tumor-infiltrating lymphocytes. Sci Transl Med (2013) 1.72
Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One (2008) 1.72